首页> 外文期刊>European Journal of Hybrid Imaging >Does addition of a diagnostic contrast-enhanced CT to a contemporaneous PET/CT provide incremental value in patients for restaging of colorectal carcinoma?
【24h】

Does addition of a diagnostic contrast-enhanced CT to a contemporaneous PET/CT provide incremental value in patients for restaging of colorectal carcinoma?

机译:在同期PET / CT上增加诊断性对比增强CT是否可以为重新分期结直肠癌的患者增加价值?

获取原文
       

摘要

Abstract BackgroundBoth constrast-enhanced computed tomography (ceCT) and 18F-Fluorodeoxyglucose positron emission tomography (PET) are widely used for evaluation of colorectal cancer. Not infrequently patients undergo both tests, increasing cost and radiation burden. Whether this combination provides useful incremental diagnostic information remains unclear. Our purpose was to determine whether the addition of ceCT to PET/CT results in an appropriate change in the N or M stage in patients with colorectal cancer.MethodsThis was a single centre, retrospective study in a tertiary referral hospital. Over 9?months, 74 consecutive patients with colorectal carcinoma were referred for PET with a recent ceCT scan and adequate follow-up were analysed. The N and M stage of each modality was compared. Management was determined according to institutional guidelines with incremental impact of ceCT results on management categorised as appropriate, inappropriate or unchanged, based on pathological results, clinical or imaging follow-up of discrepant findings.ResultsOf 74 patients, PET/CT and ceCT N and M stages were concordant in 56 patients (76%) but PET/CT and ceCT identified additional abnormalities in 9 cases each respectively. Of the 18 discordant cases, accepting the ceCT result would have appropriately changed management in only 2 patients and inappropriately in 1 with most management plans unchanged. When comparing PET/CT and ceCT, kappa agreement (95% confidence interval) for N and M stage was 0.58 (0.20–0.95) and 0.60(0.41–0.79) respectively reflecting moderate agreement.ConclusionsWhole-body ceCT probably has limited management impact in colorectal cancer patients who are also undergoing PET/CT and therefore may possibly be omitted from routine use. Targeted regional MRI or ceCT should, however, be considered based on clinical suspicion or when high-resolution anatomical information is required for treatment planning.
机译:摘要背景造影增强计算机断层扫描(ceCT)和18F-氟脱氧葡萄糖正电子发射断层扫描(PET)均被广泛用于评估结直肠癌。患者很少会同时接受两种检查,从而增加了成本和放射负担。这种组合是否提供有用的增量诊断信息尚不清楚。我们的目的是确定在大肠癌患者中将ceCT添加到PET / CT中是否会导致N或M分期的适当改变。方法这是一家三级转诊医院的单中心回顾性研究。在9个月以上的时间里,连续74例大肠癌患者接受了PET近期ceCT扫描,并进行了充分的随访。比较了每种方式的N和M阶段。根据病理学结果,临床或影像学随访发现的不同结果,根据机构指南确定ceCT结果对cect结果对管理的递增影响分为适当,不适当或不变.74例患者,PET / CT和ceCT N和M 56例患者(76%)的分期一致,但PET / CT和ceCT分别在9例中发现了其他异常。在18例不一致的病例中,接受ceCT结果将仅对2例患者适当地改变治疗,而对1例患者则不适当地改变治疗,而大多数治疗计划不变。比较PET / CT和ceCT时,N期和M期的kappa协议(95%置信区间)分别为0.58(0.20-0.95)和0.60(0.41-0.79),反映出适度的一致性。结肠直肠癌患者也正在接受PET / CT检查,因此有可能会从常规使用中剔除。然而,应基于临床怀疑或当需要高分辨率的解剖学信息以制定治疗计划时,考虑进行靶向性区域MRI或ceCT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号